149 related articles for article (PubMed ID: 2167038)
1. Activity of KB-5246 against outer membrane mutants of Escherichia coli and Salmonella typhimurium.
Kotera Y; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1990 Jul; 34(7):1323-5. PubMed ID: 2167038
[TBL] [Abstract][Full Text] [Related]
2. In vitro antibacterial activities of tosufloxacin against and uptake of tosufloxacin by outer membrane mutants of Escherichia coli, Proteus mirabilis, and Salmonella typhimurium.
Mitsuyama J; Itoh Y; Takahata M; Okamoto S; Yasuda T
Antimicrob Agents Chemother; 1992 Sep; 36(9):2030-6. PubMed ID: 1329639
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of amifloxacin against outer membrane mutants of the family Enterobacteriaceae and frequency of spontaneous resistance.
Watanabe M; Inoue M; Mitsuhashi S
Antimicrob Agents Chemother; 1989 Nov; 33(11):1837-40. PubMed ID: 2558611
[TBL] [Abstract][Full Text] [Related]
4. Differences in susceptibility to quinolones of outer membrane mutants of Salmonella typhimurium and Escherichia coli.
Hirai K; Aoyama H; Irikura T; Iyobe S; Mitsuhashi S
Antimicrob Agents Chemother; 1986 Mar; 29(3):535-8. PubMed ID: 3521490
[TBL] [Abstract][Full Text] [Related]
5. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction.
Cohen SP; McMurry LM; Hooper DC; Wolfson JS; Levy SB
Antimicrob Agents Chemother; 1989 Aug; 33(8):1318-25. PubMed ID: 2679373
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli isolates.
Tavío MM; Vila J; Ruiz J; Ruiz J; Martín-Sánchez AM; Jiménez de Anta MT
J Antimicrob Chemother; 1999 Dec; 44(6):735-42. PubMed ID: 10590273
[TBL] [Abstract][Full Text] [Related]
7. [Resistance to quinolones and beta-lactams in Salmonella enterica due to mutations in topoisomerase-encoding genes, altered cell permeability and expression of an active efflux system].
Miró E; Vergés C; García I; Mirelis B; Navarro F; Coll P; Prats G; Martínez-Martínez L
Enferm Infecc Microbiol Clin; 2004 Apr; 22(4):204-11. PubMed ID: 15056435
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo antibacterial activities of KB-5246, a new tetracyclic quinolone.
Kotera Y; Mitsuhashi S
Antimicrob Agents Chemother; 1989 Nov; 33(11):1896-900. PubMed ID: 2610501
[TBL] [Abstract][Full Text] [Related]
9. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
Pasquali F; Manfreda G
Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
[TBL] [Abstract][Full Text] [Related]
10. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
Strahilevitz J; Robicsek A; Hooper DC
Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
[TBL] [Abstract][Full Text] [Related]
11. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.
Schedletzky H; Wiedemann B; Heisig P
J Antimicrob Chemother; 1999 May; 43 Suppl B():31-7. PubMed ID: 10382873
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial Activity of DC-159a Against Salmonella Typhimurium.
Koide K; Kongsoi S; Ouchi Y; Yamaguchi T; Nakajima C; Suzuki Y
Microb Drug Resist; 2019; 25(1):14-22. PubMed ID: 30036136
[TBL] [Abstract][Full Text] [Related]
13. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
Strahilevitz J; Hooper DC
Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
[TBL] [Abstract][Full Text] [Related]
14. Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients.
Piddock LJ; Griggs DJ; Hall MC; Jin YF
Antimicrob Agents Chemother; 1993 Apr; 37(4):662-6. PubMed ID: 8494360
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Salmonella Typhimurium DNA gyrase as a target of quinolones.
Kongsoi S; Yokoyama K; Suprasert A; Utrarachkij F; Nakajima C; Suthienkul O; Suzuki Y
Drug Test Anal; 2015 Aug; 7(8):714-20. PubMed ID: 25381884
[TBL] [Abstract][Full Text] [Related]
16. Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12.
Hirai K; Aoyama H; Suzue S; Irikura T; Iyobe S; Mitsuhashi S
Antimicrob Agents Chemother; 1986 Aug; 30(2):248-53. PubMed ID: 3532944
[TBL] [Abstract][Full Text] [Related]
17. Unique biological properties and molecular mechanism of 5,6-bridged quinolones.
Macinga DR; Renick PJ; Makin KM; Ellis DH; Kreiner AA; Li M; Rupnik KJ; Kincaid EM; Wallace CD; Ledoussal B; Morris TW
Antimicrob Agents Chemother; 2003 Aug; 47(8):2526-37. PubMed ID: 12878515
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of quinolones on DNA gyrase of Escherichia coli and topoisomerase II of fetal calf thymus.
Hoshino K; Sato K; Une T; Osada Y
Antimicrob Agents Chemother; 1989 Oct; 33(10):1816-8. PubMed ID: 2556080
[TBL] [Abstract][Full Text] [Related]
19. Activity of non-fluorinated quinolones (NFQs) against quinolone-resistant Escherichia coli and Streptococcus pneumoniae.
Roychoudhury S; Twinem TL; Makin KM; McIntosh EJ; Ledoussal B; Catrenich CE
J Antimicrob Chemother; 2001 Jul; 48(1):29-36. PubMed ID: 11418510
[TBL] [Abstract][Full Text] [Related]
20. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
